Pomey Marie-Pascale, Le Roux Enora, Nadon Nathalie, Perron Jessie, Barry Angèle, Bémeur Chantal, Poder Thomas G, Duford Fernand, Laviolette Louise, Tétrault-Lassonde Johanne, Vialaron Cécile, Escalona Manuel J, Normandin Louise, Huard Geneviève, Girardin Catherine, Rose Christopher, Malas Kathy, Ouellet Denis, Vincent Catherine
Carrefour de l'Innovation, Centre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada.
Département de gestion, évaluation et politique de santé, école de santé publique, Université de Montréal, Montreal, QC, Canada.
JMIR Res Protoc. 2024 Mar 22;13:e54440. doi: 10.2196/54440.
Liver transplantation (LT) is indicated in patients with severe acute or chronic liver failure for which no other therapy is available. With the increasing number of LTs in recent years, liver centers worldwide must manage their patients according to their clinical situation and the expected waiting time for transplantation. The LT clinic at the Centre hospitalier de l'Université de Montréal (CHUM) is developing a new health care model across the entire continuum of pre-, peri-, and posttransplant care that features patient monitoring by an interdisciplinary team, including an accompanying patient; a digital platform to host a clinical plan; a learning program; and data collection from connected objects.
This study aims to (1) evaluate the outcomes following the implementation of a patient platform with connected devices and an accompanying patient, (2) identify implementation barriers and facilitators, (3) describe service outcomes in terms of health outcomes and the rates and nature of contact with the accompanying patient, (4) describe patient outcomes, and (5) assess the intervention's cost-effectiveness.
Six types of participants will be included in the study: (1) patients who received transplants and reached 1 year after transplantation before September 2023 (historical cohort or control group), (2) patients who will receive an LT between December 2023 and November 2024 (prospective cohort/intervention group), (3) relatives of those patients, (4) accompanying patients who have received an LT and are interested in supporting patients who will receive an LT, (5) health care professionals, and (6) decision makers. To describe the study sample and collect data to achieve all the objectives, a series of validated questionnaires, accompanying patient logbooks, transcripts of interviews and focus groups, and clinical indicators will be collected throughout the study.
In total, 5 (steering, education, clinical-technological, nurse prescription, and accompanying patient) working committees have been established for the study. Recruitment of patients is expected to start in November 2023. All questionnaires and technological platforms have been prepared, and the clinicians, stakeholders, and accompanying patient personnel have been recruited.
The implementation of this model in the trajectory of LT recipients at the CHUM may allow for better monitoring and health of patients undergoing transplantation, ultimately reducing the average length of hospital stay and promoting better use of medical resources. In the event of positive results, this model could be transposed to all transplant units at the CHUM and across Quebec (potentially affecting 888 patients per year) but could also be applied more widely to the monitoring of patients with other chronic diseases. The lessons learned from this project will be shared with decision makers and will serve as a model for other initiatives involving accompanying patients, connected objects, or digital platforms.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/54440.
肝移植(LT)适用于患有严重急性或慢性肝衰竭且无其他可用治疗方法的患者。近年来,随着肝移植数量的增加,全球各肝脏中心必须根据患者的临床情况和预期等待移植时间来管理患者。蒙特利尔大学中心医院(CHUM)的肝移植诊所正在开发一种全新的医疗保健模式,覆盖移植前、移植中和移植后的整个连续过程,其特点包括由跨学科团队(包括一名陪同患者)进行患者监测;一个用于承载临床计划的数字平台;一个学习项目;以及从连接设备收集数据。
本研究旨在(1)评估实施带有连接设备和陪同患者的患者平台后的结果,(2)识别实施障碍和促进因素,(3)从健康结果以及与陪同患者接触的频率和性质方面描述服务结果,(4)描述患者结果,以及(5)评估该干预措施的成本效益。
研究将纳入六种类型的参与者:(1)在2023年9月前接受移植且移植后满1年的患者(历史队列或对照组),(2)在2023年12月至2024年11月期间将接受肝移植的患者(前瞻性队列/干预组),(3)这些患者的亲属,(4)已接受肝移植且有意愿支持即将接受肝移植患者的陪同患者,(5)医护人员,以及(6)决策者。为了描述研究样本并收集数据以实现所有目标,在整个研究过程中将收集一系列经过验证的问卷、陪同患者日志、访谈和焦点小组记录以及临床指标。
总共为该研究设立了5个工作委员会(指导、教育、临床技术、护士处方和陪同患者)。预计患者招募将于2023年11月开始。所有问卷和技术平台均已准备就绪,临床医生、利益相关者和陪同患者人员也已招募到位。
在CHUM的肝移植受者治疗过程中实施此模式,可能有助于更好地监测移植患者的健康状况,最终缩短平均住院时间并促进医疗资源的更合理利用。如果结果呈阳性,该模式可推广至CHUM的所有移植科室以及魁北克省(每年可能影响888名患者),但也可更广泛地应用于其他慢性病患者的监测。从该项目中吸取的经验教训将与决策者分享,并可作为涉及陪同患者、连接设备或数字平台的其他举措的典范。
国际注册报告识别码(IRRID):PRR1 - 10.2196/54440。